Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853 |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP, other |
| Sample | GC cell line AGS |
| Expression Pattern | up-regulated |
| Function Description | Cell viability was markedly increased in MALAT1-overexpressing AGS/CDDP cells, but was notably reduced in MALAT1-depleted HGC-27/CDDP cells. Moreover, MALAT1 potentiated CDDP resistance by facilitating autophagy in AGS/CDDP and HGC-27/CDDP cells. Further investigations demonstrated that MALAT1 inhibited miR-30b expression by direct interaction. Moreover, miR-30b abolished MALAT1-induced CDDP resistance by inhibiting autophagy in AGS/CDDP and HGC-27/CDDP cells. Furthermore, ATG5 was found to be a target of miR-30b. miR-30b weakened resistance to CDDP by inhibiting autophagy in AGS/CDDP and HGC-27/CDDP cells, while this effect was abrogated by increased ATG5 expression. Additionally, MALAT1 sequestered miR-30b from ATG5 to increase ATG5 expression in AGS/CDDP and HGC-27/CDDP cells. |
| Pubmed ID | 30365113 |
| Year | 2019 |
| Title | LncRNA MALAT1 Potentiates Autophagy-associated Cisplatin Resistance by Regulating the microRNA-30b/autophagy-related Gene 5 Axis in Gastric Cancer |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |